Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Molecular diagnostics for advanced ovarian cancer (AOC) guide PARP inhibitor (PARPi) treatment. This study found genetic variants beyond HRD status impact PARPi response, suggesting new biomarkers for personalized therapy.
Area Of Science
- Oncology
- Genetics
- Pharmacology
Background
- Advanced epithelial ovarian cancer (AOC) management benefits from molecular diagnostics predicting response to Poly (ADP-ribose) polymerase inhibitors (PARPi).
- Homologous recombination deficiency (HRD) status is a key biomarker, but its predictive power for PARPi sensitivity is inconsistent.
- Understanding resistance mechanisms beyond HRD is crucial for optimizing treatment strategies.
Purpose Of The Study
- To investigate molecular factors influencing PARPi sensitivity and resistance in AOC, beyond established HRD status.
- To identify novel genetic variants associated with treatment response and progression-free survival (PFS).
- To explore the role of specific BRCA1 variants in predicting response to combination therapy.
Main Methods
- Post hoc translational analysis of tumor samples from the ENGOT-ov24/NSGO-AVANOVA trial.
- DNA sequencing using the TruSight Oncology 500 HT gene panel on formalin-fixed paraffin-embedded samples.
- Classification of variants and assessment of HRD status using Myriad MyChoice CDx.
Main Results
- 151 pathogenic/likely pathogenic variants were identified in 81 samples from 92 patients.
- PARPi-sensitizing variants were found in HRD-negative patients with clinical benefit, and resistance variants in HRD-positive patients with poor outcomes.
- Truncating BRCA1 variants in exon 11 correlated with improved PFS when niraparib was combined with bevacizumab.
Conclusions
- PARPi response in AOC is complex and influenced by genetic alterations beyond HRD status.
- Somatic variant analysis offers potential for identifying novel biomarkers for PARPi therapy.
- Further research into BRCA1 exon 11 variants and combination therapies is warranted for precision oncology in AOC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...